Related references
Note: Only part of the references are listed.Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
G. L. Goll et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Are we ready to close the discussion on the interchangeability of biosimilars?
Hans C. Ebbers et al.
DRUG DISCOVERY TODAY (2019)
Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study
Valeria Belleudi et al.
DRUG SAFETY (2019)
Sowing confusion in the field: the interchangeable use of biosimilar terminology
Laura McKinley et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence
Gianluca Trifiro et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study
S. Gerdes et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2018)
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
A. Blauvelt et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
Paul Declerck et al.
CLINICAL THERAPEUTICS (2018)
Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
Hillel P. Cohen et al.
DRUGS (2018)
The Science Behind Biosimilars Entering a New Era of Biologic Therapy
S. Louis Bridges et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
Lars Erik Kristensen et al.
BIODRUGS (2018)
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy
Francesco Trotta et al.
BMJ OPEN (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Interchangeability of Biosimilars: A European Perspective
Pekka Kurki et al.
BIODRUGS (2017)
How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009-2014
Ilaria Marciano et al.
BIODRUGS (2016)
Differentiating biosimilarity and comparability in biotherapeutics
Valderilio Azevedo et al.
CLINICAL RHEUMATOLOGY (2016)
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study
Ylenia Ingrasciotta et al.
PLOS ONE (2016)
Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
K. Blackwell et al.
ANNALS OF ONCOLOGY (2015)
How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013
Ylenia Ingrasciotta et al.
BIODRUGS (2015)
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Michael Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Statistical and regulatory considerations in assessments of interchangeability of biological drug products
Laszlo Tothfalusi et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
The safety of switching between therapeutic proteins
Hans C. Ebbers et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Nocebo Effects, Patient-Clinician Communication, and Therapeutic Outcomes
Luana Colloca et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The Nocebo Effect and Its Relevance for Clinical Practice
Luana Colloca et al.
PSYCHOSOMATIC MEDICINE (2011)
Epoetin-induced autoinmune pure red cell aplasia
N Casadevall et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk
D Cournoyer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2004)
Pure red-cell aplasia and epoetin therapy
CL Bennett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N Casadevall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Nonspecific medication side effects and the nocebo phenomenon
AJ Barsky et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Share Paper
